Literature DB >> 6342098

Empiric therapy for pneumonia.

G R Donowitz, G L Mandell.   

Abstract

Bacterial pneumonia remains a serious infectious disease even in the modern era of antibiotics and still causes significant morbidity and mortality. Because of the large number of organisms that may cause pulmonary disease, the inexactness of commonly used diagnostic techniques, and the serious consequences of untreated disease, empiric therapy has become accepted practice. Empiric therapy should be designed for treatment of the most likely etiologic organisms while minimizing the potential adverse effects of "shotgun" therapy: drug toxicity, superinfection, and excessive cost. The recognition of common pneumonia syndromes helps narrow the spectrum of possible etiologic agents and consequently aids in the design of rational empiric antibiotic therapy.

Entities:  

Mesh:

Year:  1983        PMID: 6342098     DOI: 10.1093/clinids/5.supplement_1.s40

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

Review 1.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Adaptive mutations produce resistance to ciprofloxacin.

Authors:  C Riesenfeld; M Everett; L J Piddock; B G Hall
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

4.  Comparative in vitro activity of A-56268 against respiratory tract pathogens.

Authors:  L Jansson; M Kalin
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

5.  Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.

Authors:  D Williams; M Perri; M J Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.